MCID: HYP063
MIFTS: 53

Hypersplenism

Categories: Blood diseases, Immune diseases

Aliases & Classifications for Hypersplenism

MalaCards integrated aliases for Hypersplenism:

Name: Hypersplenism 12 54 43 15 17 71 32
Hypersplenia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6376
ICD9CM 34 289.4
MeSH 43 D006971
NCIt 49 C34714
SNOMED-CT 67 58381000
ICD10 32 D73.1
UMLS 71 C0020532

Summaries for Hypersplenism

MalaCards based summary : Hypersplenism, also known as hypersplenia, is related to esophageal varix and splenic abscess. An important gene associated with Hypersplenism is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Tacrolimus and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and bone, and related phenotypes are immune system and hematopoietic system

Wikipedia : 74 Splenomegaly is an enlargement of the spleen. The spleen usually lies in the left upper quadrant (LUQ)... more...

Related Diseases for Hypersplenism

Diseases related to Hypersplenism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 551)
# Related Disease Score Top Affiliating Genes
1 esophageal varix 30.9 SERPINC1 GPT F2 ALB
2 splenic abscess 30.8 GPT F2 ALB
3 splenic infarction 30.7 SERPINC1 GPT F2
4 ileus 30.7 IFNG F2 CSF2
5 sickle cell anemia 30.6 F2 EPO CSF3 ALB
6 paralytic ileus 30.4 GPT F2 ALB
7 liver cirrhosis 30.4 THPO SERPINC1 GPT F2 ALB
8 q fever 30.3 TLR4 IL4 IFNG
9 endocarditis 30.3 SERPINC1 IFNG F2 ALB
10 mycobacterium tuberculosis 1 30.3 TLR4 IL4 IFNG CD4
11 dysentery 30.2 TLR4 CD4 ALB
12 portal hypertension 30.2 TLR4 THPO GPT F2 CD4 ALB
13 paroxysmal nocturnal hemoglobinuria 30.2 SERPINC1 F2 CSF3
14 abdominal tuberculosis 30.1 IFNG F2 CD4 ALB
15 peripheral vascular disease 30.1 SERPINC1 F2 EPO ALB
16 schistosomiasis 30.1 IL4 IFNG GPT F2 ALB
17 biliary atresia 30.1 IFNG GPT F2 ALB
18 splenic sequestration 30.1 THPO F2 EPO CD4
19 purpura 30.1 THPO SERPINC1 IL4 F2
20 hepatic encephalopathy 30.1 GPT F2 ALB
21 hepatic coma 30.0 SERPINC1 GPT F2 ALB
22 intestinal volvulus 30.0 GPT F2 ALB
23 hepatorenal syndrome 30.0 GPT F2 ALB
24 syphilis 29.9 GPT CD4 ALB
25 peritonitis 29.9 TLR4 IL4 IFNG F2 CSF3 ALB
26 bilirubin metabolic disorder 29.9 GPT F2 ALB
27 candidiasis 29.9 TLR4 IL4 IFNG CSF2
28 toxic shock syndrome 29.9 TLR4 SERPINC1 IL4 IFNG
29 aphthous stomatitis 29.8 TLR4 IL4 IFNG CSF2
30 neutropenia 29.8 THPO GPT EPO CSF3 CSF2
31 toxoplasmosis 29.7 TLR4 IL4 IFNG
32 thymoma 29.7 IL4 FOXP3 EGF CSF3
33 bacterial infectious disease 29.7 TLR4 IFNG CSF3 CSF2 CD4
34 combined t cell and b cell immunodeficiency 29.7 IL7R IL4 FOXP3 CD4
35 hepatitis b 29.7 TLR4 IFNG GPT F2 ALB
36 visceral leishmaniasis 29.6 TLR4 IL4 IFNG FOXP3 ALB
37 brucellosis 29.6 TLR4 IL4 IL2RA IFNG
38 respiratory failure 29.5 GPT F2 EPO CD4 ALB
39 adult t-cell leukemia 29.4 REL IL2RA FOXP3 CD4
40 acquired immunodeficiency syndrome 29.4 IL2RA IFNG EPO CSF2 CD4 ALB
41 autoimmune hepatitis 29.4 IL4 GPT FOXP3 F2 ALB
42 stomatitis 29.3 TLR4 IL4 IFNG CSF3 CSF2 CD4
43 cholecystitis 29.2 TLR4 GPT F2 EGF ALB
44 deficiency anemia 29.2 THPO FOXP3 EPO CSF3 CSF2 BMP6
45 myeloproliferative neoplasm 29.2 THPO EPO CSF3 CSF2
46 hemoglobinuria 29.2 THPO SERPINC1 F2 EPO CSF3
47 viral hepatitis 29.1 TLR4 IL4 IFNG GPT F2 ALB
48 heart disease 29.1 TLR4 SERPINC1 GPT F2 EPO CD4
49 myelofibrosis 29.0 THPO IL2RA EPO CSF3 BMP6
50 pancytopenia 29.0 THPO IL2RA IFNG FOXP3 EPO CSF3

Comorbidity relations with Hypersplenism via Phenotypic Disease Network (PDN): (show all 12)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Alcoholic Liver Cirrhosis
Chronic Congestive Splenomegaly Deficiency Anemia
Heart Disease Hepatic Encephalopathy
Iron Deficiency Anemia Neutropenia
Portal Hypertension Primary Thrombocytopenia

Graphical network of the top 20 diseases related to Hypersplenism:



Diseases related to Hypersplenism

Symptoms & Phenotypes for Hypersplenism

MGI Mouse Phenotypes related to Hypersplenism:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.39 ALB CD4 CSF2 CSF3 EGF EPO
2 hematopoietic system MP:0005397 10.37 CD4 CSF2 CSF3 EPO F2 FOXP3
3 homeostasis/metabolism MP:0005376 10.32 ALB CD4 CSF2 EPO F2 FOXP3
4 cardiovascular system MP:0005385 10.3 ALB CSF2 EPO F2 FOXP3 IFNG
5 cellular MP:0005384 10.29 ALB CD4 CSF2 EPO FOXP3 IFNG
6 growth/size/body region MP:0005378 10.29 BMP6 CD4 CSF2 EGF F2 FOXP3
7 digestive/alimentary MP:0005381 10.24 ALB CD4 EGF F2 FOXP3 IFNG
8 endocrine/exocrine gland MP:0005379 10.22 ALB CD4 CSF2 EGF FOXP3 IFNG
9 integument MP:0010771 10.21 CD4 CSF2 CSF3 EGF EPO F2
10 mortality/aging MP:0010768 10.18 ALB CD4 CSF2 EPO F2 FOXP3
11 normal MP:0002873 10.1 ALB CD4 EGF EPO F2 FOXP3
12 liver/biliary system MP:0005370 10.06 ALB EPO FOXP3 IFNG IL4 PIK3R1
13 renal/urinary system MP:0005367 9.86 ALB CSF2 CSF3 FOXP3 IFNG IL4
14 reproductive system MP:0005389 9.81 BMP6 CSF2 EGF F2 FOXP3 IFNG
15 respiratory system MP:0005388 9.61 CSF2 EPO F2 FOXP3 IFNG IL2RA
16 skeleton MP:0005390 9.32 BMP6 CSF2 EPO F2 GPT IFNG

Drugs & Therapeutics for Hypersplenism

Drugs for Hypersplenism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
2
Mycophenolic acid Approved Phase 4 24280-93-1 446541
3
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
4
Dalteparin Approved Phase 4 9005-49-6
5
tannic acid Approved Phase 4 1401-55-4
6
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
7
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
8
Dipyridamole Approved Phase 4 58-32-2 3108
9
Warfarin Approved Phase 4 81-81-2 6691 54678486
10
Nadroparin Approved, Investigational Phase 4
11
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
12 Antibiotics, Antitubercular Phase 4
13 Anti-Bacterial Agents Phase 4
14 Antitubercular Agents Phase 4
15 Liver Extracts Phase 4
16 Fibrinolytic Agents Phase 4
17 Anticoagulants Phase 4
18 Platelet Aggregation Inhibitors Phase 4
19 Antipyretics Phase 4
20 Analgesics, Non-Narcotic Phase 4
21 Anti-Inflammatory Agents, Non-Steroidal Phase 4
22 Analgesics Phase 4
23 Vasodilator Agents Phase 4
24 Cyclooxygenase Inhibitors Phase 4
25 Calcium, Dietary Phase 4
26 Heparin, Low-Molecular-Weight Phase 4
27 Phosphodiesterase Inhibitors Phase 4
28 calcium heparin Phase 4
29
Epirubicin Approved Phase 1, Phase 2 56420-45-2 41867
30
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 6055-19-2, 50-18-0 2907
31
Valproic acid Approved, Investigational Phase 1, Phase 2 99-66-1 3121
32
Melphalan Approved Phase 2 148-82-3 4053 460612
33
Lenalidomide Approved Phase 2 191732-72-6 216326
34
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
35
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
36 Topoisomerase Inhibitors Phase 1, Phase 2
37 Neurotransmitter Agents Phase 1, Phase 2
38 Central Nervous System Depressants Phase 1, Phase 2
39 Anticonvulsants Phase 1, Phase 2
40 Tranquilizing Agents Phase 1, Phase 2
41 Psychotropic Drugs Phase 1, Phase 2
42 GABA Agents Phase 1, Phase 2
43 Antimanic Agents Phase 1, Phase 2
44 Alkylating Agents Phase 2
45 Angiogenesis Inhibitors Phase 2
46 Protein Kinase Inhibitors Phase 2
47 Antimetabolites Phase 2
48
Oprelvekin Approved, Investigational 145941-26-0
49
Gemcitabine Approved 95058-81-4 60750
50
Carboplatin Approved 41575-94-4 10339178 498142 38904

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 Comparison Of Efficacy Of Two Immunosuppressive Protocols Including Tacrolimus With Or Without Mycophenolate Mofetil In Pediatric Liver Transplantation Aimed In Early Termination Of Steroid Therapy Completed NCT00195988 Phase 4 tacrolimus, steroids, mycophenolate mofetil
2 Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Recruiting NCT02238444 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
3 Autologous Bone Marrow Stem Cells Infusion Through Hepatic Artery in Open Abdominal Portal Hypertension Surgery for the Treatment of Liver Cirrhosis: a Prospective, Non-randomized, Controlled Study Unknown status NCT01560845 Phase 2, Phase 3
4 A Prospective Phase II Randomized, Blinded Study to Demonstrate the Effectiveness of Jobelyn for the Treatment of Breast Cancer Patients. Unknown status NCT01936064 Phase 1, Phase 2 Placebo + Cyclophosphamide - Epirubicin 6
5 An Open Label Multicenter Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 in Adult Subjects With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency Who Previously Received Treatment in Study LAL-CL01 Completed NCT01488097 Phase 2 sebelipase alfa
6 An Open-Label Multicenter Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SBC-102 in Adult Participants With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency Completed NCT01307098 Phase 1, Phase 2 Sebelipase alfa 0.35 mg/kg;Sebelipase alfa 1 mg/kg;Sebelipase alfa 3 mg/kg
7 Pilot (Phase I-II) Study of Valproic Acid (Depakote) for the Treatment of the Autoimmune Lymphoproliferative Syndrome (ALPS) Completed NCT00605657 Phase 1, Phase 2 Valproic Acid
8 Revlimid®, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: A Phase 2 Study" Completed NCT00744536 Phase 2 Lenalidomide and melphalan
9 A Phase II Trial of Sorafenib Plus Tegafur-uracil (UFT) vs. Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation &/or TACE Terminated NCT01539018 Phase 2 Sorafenib;sorafenib plus tegafur-uracil
10 Hypersplenism in Patients With Liver Cirrhosis and Portal Hypertension: Prevalence, Pattern, Correlations, and Therapy Unknown status NCT03269877
11 Comparative Study of Microwave Ablation and Partial Splenic Embolization in the Management of Hypersplenism Unknown status NCT02261584
12 Multicentric Retrospective Case Control Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis Unknown status NCT01201655
13 The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC Receiving Gemcitabine and Cisplatin or Carboplatin Chemotherapy Unknown status NCT02344979
14 A Randomized Controlled Trial of Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection Completed NCT00825669 TACE
15 The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia. Clinical Presentation and Follow up. Splenectomy, Indications and Complications. Completed NCT00971698
16 Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic Portal Vein Thrombosis in HCV Related Compensated Cirrhosis Completed NCT03201367 Rivaroxaban
17 The Treatment of Gastroesophageal Varices Accompanied With Splenomegaly or Hypersplenism of Hepatocirrhosis and Portal Hypertension Recruiting NCT02778425
18 Differential Diagnostic of ITP and MDS: a Prospective Study by Next‐Generation Flow Cytometry and Cytomorphological Approaches Recruiting NCT03469661
19 HVPG-guided Laparoscopic Versus Endoscopic Therapy for Variceal Rebleeding in Portal Hypertension: A Multicenter Randomized Controlled Trial (CHESS1803) Recruiting NCT03783065 Propranolol
20 Management of Childhood Pancytopenia in Heamatology Unit in Assiut University Hospital Not yet recruiting NCT03521947
21 Gall Bladder Status Among Children With Chronic Haemolytic Anemia Attending to Assuit University Children Hospital Not yet recruiting NCT03533322
22 Viral Hepatitis B and C Infection in Patients With Idiopathic Thrombocytopenic Purpura Treated With Triple Therapy Not yet recruiting NCT04113915 triple therapy;Steroids
23 Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder Terminated NCT00722254

Search NIH Clinical Center for Hypersplenism

Cochrane evidence based reviews: hypersplenism

Genetic Tests for Hypersplenism

Anatomical Context for Hypersplenism

MalaCards organs/tissues related to Hypersplenism:

40
Liver, Spleen, Bone, Bone Marrow, Kidney, Myeloid, T Cells

Publications for Hypersplenism

Articles related to Hypersplenism:

(show top 50) (show all 2061)
# Title Authors PMID Year
1
Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection. 54 61
16215425 2005
2
Platelet count increase following phlebotomy in iron overloaded patients with liver cirrhosis. 61 54
12911944 2003
3
Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver diseases. 54 61
12753144 2003
4
Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. 54 61
12399221 2002
5
Role of plasma thrombopoietin level in thrombocytopenia of postoperative biliary atresia patients. 61 54
12149701 2002
6
Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma. 54 61
11787473 2000
7
Thrombocytopenia associated with liver cirrhosis and hepatitis C viral infection: role of thrombopoietin. 61 54
11100362 2000
8
Laparoscopic cholecystectomy for cholelithiasis in patients with liver cirrhosis. 61 54
18493357 1995
9
FDG-PET/CT Demonstrates Splenic Angiosarcoma Bone Marrow Metastasis. 61
31306197 2020
10
Distal Splenorenal Shunt (DSRS) in Children with Extrahepatic Portal Hypertension. 61
31839103 2019
11
Effects of laparoscopic splenectomy and azygoportal disconnection on liver synthesis function and cirrhosis: a 2-year prospective study. 61
31820157 2019
12
Improvement of human platelet aggregation post-splenectomy with paraesophagogastric devascularization in chronic hepatitis B patients with cirrhotic hypersplenism. 61
31851564 2019
13
Novel Therapeutic Strategy Using Interventional Radiology (IVR) for Hepatitis C Virus (HCV)-Related Decompensated Liver Cirrhosis: A Case Report. 61
31738743 2019
14
Patterns of splenic arterial enhancement on computed tomography scan are related to portal venous hypertension. 61
31490421 2019
15
Impact of imbalanced graft-to-spleen volume ratio on outcomes following living donor liver transplantation in an era when simultaneous splenectomy is not typically indicated. 61
30830721 2019
16
Abnormal glucose metabolism in patients with Fontan circulation: Unique characteristics and associations with Fontan pathophysiology. 61
31425899 2019
17
Splenic serum from portal hypertensive patients enhances liver stem cell proliferation and self-renewal via the IGF-II/ERK signaling pathway. 61
31495600 2019
18
Rapid increase of platelet counts during antiviral therapy in patients with hepatitis C virus infection. 61
31496023 2019
19
Emergency or urgent splenectomy in children for non-traumatic reasons. 61
31312939 2019
20
Endovascular treatment of surgical mesoportal and portosystemic shunt dysfunction in pediatric patients. 61
31273428 2019
21
Clinical Characteristics and Risk Factors for Sinistral Portal Hypertension Associated with Moderate and Severe Acute Pancreatitis: A Seven-Year Single-Center Retrospective Study. 61
31400275 2019
22
The Effects of Liver Transplantation in Children With Niemann-Pick Disease Type B. 61
30912297 2019
23
Etiology, presenting features and outcome of children with non-cirrhotic portal vein thrombosis: A multicentre national study. 61
30928422 2019
24
From sadness to stiffness: the spleen's progress. 61
31152307 2019
25
Partial Splenic Artery Embolization in 35 Cancer Patients: Results of a Single Institution Retrospective Study. 61
31471193 2019
26
Clinical features of idiopathic portal hypertension in China: A retrospective study of 338 patients and literature review. 61
30462857 2019
27
Graft Hepatic Artery Rupture Due to Carbapenem-Resistant Klebsiella pneumoniae Infection After Liver Transplant. 61
31424357 2019
28
Comparison of early postoperative results between robot-assisted and laparoscopic splenectomy for non-traumatic splenic diseases rather than portal hypertensive hypersplenism-a meta-analysis. 61
31350089 2019
29
Immunological consequences following splenectomy in patients with liver cirrhosis. 61
31281459 2019
30
Multiple Giant Splenic Artery Aneurysms with Hypersplenism and Portal Hypertension: A Case Report. 61
31275486 2019
31
Recanalization of Chronic Portal Vein Occlusion in Pediatric Liver Transplant Patients. 61
30773434 2019
32
Dual-interventional therapy for multiple splenic artery aneurysms in a patient with portal hypertension: A case report. 61
31083153 2019
33
Splenic devascularization can replace splenectomy during adult living donor liver transplantation - a historical cohort study. 61
30714245 2019
34
Simultaneous radiofrequency ablation combined with laparoscopic splenectomy: a safe and effective way for patients with hepatocellular carcinoma complicated with cirrhosis and hypersplenism. 61
31116622 2019
35
Laparoscopic selective esophagogastric devascularization and splenectomy for patients with cirrhotic portal hypertension. 61
31118982 2019
36
Patterns of splenic arterial enhancement on computed tomography are related to changes in portal venous pressure. 61
30334908 2019
37
Splenectomy to Optimize Hemoglobin S Control in Children With Sickle Cell Anemia on Chronic Transfusion Therapy for Stroke Prevention. 61
29668544 2019
38
Massive Splenic Infarction in a Child With Sickle Cell Disease on Chronic Transfusion Therapy. 61
30499910 2019
39
Extra Hepatic Portal Vein Obstruction with Solitary Left Kidney: A Case Report. 61
31477949 2019
40
Efficacy and safety of partial splenic embolization for hypersplenism in pre- and post-liver transplant patients: A 16-year comparative analysis. 61
30553121 2019
41
Partial splenic embolization with Glubran®2/Lipiodol® mixture for oncological patients with hypersplenism-related thrombocytopenia requiring systemic chemotherapy. 61
31032188 2019
42
Adverse factors responsible for below-normal platelet count after laparoscopic splenectomy and azygoportal disconnection. 61
30460896 2019
43
Coronary Renal Shunt with Splenectomy (CRSS) for Selective Variceal Decompression. 61
30225560 2019
44
Mutation in ITCH Gene Can Cause Syndromic Multisystem Autoimmune Disease With Acute Liver Failure. 61
30705142 2019
45
Long-Term Results after Diversion Surgery in Extrahepatic Portal Vein Obstruction. 61
30086576 2019
46
Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. 61
29886103 2019
47
Radical surgical treatment of Budd-Chiari syndrome through entire exposure of hepatic inferior vena cava. 61
30341019 2019
48
The effect of splenectomy on complement regulatory proteins in erythrocytes in β-thalassemia major. 61
30697270 2019
49
Elective Splenectomy Combined with Modified Hassab's or Sugiura Procedure for Portal Hypertension in Decompensated Cirrhosis. 61
31183338 2019
50
[Latent essential thrombocythemia becoming perceptible after splenectomy]. 61
31168000 2019

Variations for Hypersplenism

Expression for Hypersplenism

Search GEO for disease gene expression data for Hypersplenism.

Pathways for Hypersplenism

Pathways related to Hypersplenism according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 TLR4 REL PIK3R1 IL7R IL4 IL2RA
2
Show member pathways
13.83 THPO PIK3R1 IL7R IL4 IL2RA EGF
3
Show member pathways
13.56 TLR4 THPO PIK3R1 IL7R IL4 IL2RA
4
Show member pathways
13.53 THPO PIK3R1 IL7R IL4 IL2RA IFNG
5
Show member pathways
13.36 PIK3R1 IL7R IL4 IL2RA IFNG EGF
6
Show member pathways
13.33 THPO SERPINC1 PIK3R1 IL2RA F2 EGF
7
Show member pathways
13.32 TLR4 THPO PIK3R1 IL7R IL4 IL2RA
8
Show member pathways
13.26 THPO PIK3R1 IL7R IL4 IL2RA EGF
9
Show member pathways
13.07 THPO PIK3R1 IL4 IL2RA F2 EGF
10
Show member pathways
12.99 TLR4 PIK3R1 IL7R IL4 IL2RA EPO
11
Show member pathways
12.85 IL4 IL2RA IFNG FOXP3 CD4
12 12.8 PIK3R1 IL7R IL4 IL2RA IFNG F2
13
Show member pathways
12.78 THPO PIK3R1 IL7R IL4 IL2RA
14
Show member pathways
12.73 TLR4 THPO REL PIK3R1 EGF BMP6
15
Show member pathways
12.67 REL PIK3R1 IFNG EGF CD4
16
Show member pathways
12.66 REL PIK3R1 IL4 IL2RA IFNG CD4
17
Show member pathways
12.63 TLR4 IL4 IL2RA IFNG FOXP3 CD4
18
Show member pathways
12.6 REL PIK3R1 IFNG F2 CD4
19 12.58 REL IL4 IL2RA IFNG FOXP3
20
Show member pathways
12.47 TLR4 REL PIK3R1 IL4 IFNG EGF
21
Show member pathways
12.37 REL IL4 IFNG CSF3 CSF2
22 12.34 PIK3R1 IL2RA CSF2 CD4
23
Show member pathways
12.33 IL4 IFNG F2 ALB
24
Show member pathways
12.28 THPO IL4 IL2RA IFNG BMP6
25 12.2 TLR4 PIK3R1 IFNG EGF
26
Show member pathways
12.2 TLR4 REL IL4 IFNG
27
Show member pathways
12.08 TLR4 IL4 IFNG F2 CSF2
28
Show member pathways
12.03 REL IL4 IL2RA IFNG CD4
29 12 TLR4 PIK3R1 IFNG EPO EGF
30 11.96 TLR4 PIK3R1 IFNG CSF2
31
Show member pathways
11.9 TLR4 REL FOXP3 CSF3 CSF2
32 11.88 PIK3R1 IL7R IL2RA IFNG EPO EGF
33 11.83 IL7R IL4 IL2RA IFNG CD4
34 11.81 IL4 IFNG CSF2
35 11.79 TLR4 IFNG CSF2
36 11.79 IL7R IFNG CSF2 CD4
37
Show member pathways
11.79 IL4 IL2RA IFNG FOXP3 CSF2
38 11.75 THPO IL7R IL4 IL2RA EPO CSF3
39
Show member pathways
11.74 PIK3R1 IL4 IL2RA FOXP3
40 11.73 IL4 IFNG CSF2
41 11.71 IL4 EGF CSF3 CSF2
42
Show member pathways
11.69 THPO PIK3R1 IL7R IL4 IL2RA IFNG
43
Show member pathways
11.67 REL IFNG CSF2
44 11.67 THPO IL7R IL4 IL2RA IFNG EPO
45 11.57 TLR4 IFNG CSF3
46 11.56 IL4 CSF3 CSF2
47 11.55 TLR4 PIK3R1 IFNG
48 11.54 EPO CSF3 CSF2
49
Show member pathways
11.52 PIK3R1 IL7R IL2RA
50 11.43 IL4 IL2RA IFNG FOXP3 CD4

GO Terms for Hypersplenism

Cellular components related to Hypersplenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 THPO SERPINC1 IL7R IL4 IFNG F2
2 external side of plasma membrane GO:0009897 9.55 TLR4 IL7R IL2RA F2 CD4
3 clathrin-coated vesicle membrane GO:0030665 9.43 IL7R EGF CD4
4 extracellular space GO:0005615 9.4 THPO SERPINC1 IL4 IFNG GPT F2

Biological processes related to Hypersplenism according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.2 TLR4 THPO PIK3R1 IL7R IL4 EPO
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.15 TLR4 REL PIK3R1 IL4 FOXP3 CSF3
3 positive regulation of transcription, DNA-templated GO:0045893 10.01 REL IL4 FOXP3 EPO EGF CD4
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 TLR4 THPO EPO CD4
5 positive regulation of protein phosphorylation GO:0001934 9.89 THPO IFNG F2 CD4
6 cell surface receptor signaling pathway GO:0007166 9.89 IL7R IL2RA IFNG F2 CD4
7 positive regulation of protein kinase B signaling GO:0051897 9.88 THPO PIK3R1 EGF CSF3
8 cytokine-mediated signaling pathway GO:0019221 9.8 PIK3R1 IL7R IL4 IL2RA CSF3 CSF2
9 negative regulation of neuron death GO:1901215 9.79 REL EPO CSF3
10 positive regulation of T cell proliferation GO:0042102 9.79 IL4 IL2RA CD4
11 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.78 EGF CSF3 CD4 BMP6
12 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.76 PIK3R1 F2 EPO CSF3
13 positive regulation of gene expression GO:0010628 9.76 TLR4 IL7R IL4 IFNG FOXP3 EGF
14 T cell activation GO:0042110 9.75 IL4 FOXP3 CD4
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 IL4 IFNG EPO CSF2
16 negative regulation of osteoclast differentiation GO:0045671 9.69 TLR4 PIK3R1 IL4
17 regulation of blood coagulation GO:0030193 9.64 SERPINC1 F2
18 macrophage activation GO:0042116 9.63 TLR4 CSF2
19 cellular response to granulocyte macrophage colony-stimulating factor stimulus GO:0097011 9.63 CSF2 CD4
20 positive regulation of cell proliferation GO:0008284 9.61 THPO IL7R IFNG F2 EPO EGF
21 negative regulation of lymphocyte proliferation GO:0050672 9.6 IL2RA FOXP3
22 regulation of regulatory T cell differentiation GO:0045589 9.58 IL2RA IFNG FOXP3
23 neuroinflammatory response GO:0150076 9.57 IL4 IFNG
24 positive regulation of interleukin-23 production GO:0032747 9.56 IFNG CSF2
25 negative regulation of interleukin-17 production GO:0032700 9.54 TLR4 IFNG FOXP3
26 positive regulation of cellular respiration GO:1901857 9.52 IL4 IFNG
27 positive regulation of MHC class II biosynthetic process GO:0045348 9.5 TLR4 IL4 IFNG
28 immune response GO:0006955 9.28 TLR4 IL7R IL4 IL2RA IFNG CSF3

Molecular functions related to Hypersplenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.5 THPO IL4 IFNG EPO CSF3 CSF2
2 growth factor activity GO:0008083 9.17 THPO IL4 F2 EGF CSF3 CSF2

Sources for Hypersplenism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....